Celebrex Low Dose ASA Study Examining the Incidence of Gastroduodenal Ulcers in a Healthy Population

PHASE4CompletedINTERVENTIONAL
Enrollment

605

Participants

Timeline

Start Date

September 30, 2004

Study Completion Date

July 31, 2005

Conditions
Peptic Ulcers
Interventions
DRUG

Celecoxib

DRUG

Naproxen

DRUG

ASA

Trial Locations (23)

10021

Pfizer Investigational Site, New York

16635

Pfizer Investigational Site, Duncansville

20815

Pfizer Investigational Site, Chevy Chase

22903

Pfizer Investigational Site, Charlottesville

27612

Pfizer Investigational Site, Raleigh

28401

Pfizer Investigational Site, Wilmington

33024

Pfizer Investigational Site, Pembroke Pines

33173

Pfizer Investigational Site, Miami

33458

Pfizer Investigational Site, Jupiter

34761

Pfizer Investigational Site, Ocoee

37404

Pfizer Investigational Site, Chattanooga

45219

Pfizer Investigational Site, Cincinnati

47630

Pfizer Investigational Site, Newburgh

52807

Pfizer Investigational Site, Davenport

70001

Pfizer Investigational Site, Metairie

77074

Pfizer Investigational Site, Houston

77090

Pfizer Investigational Site, Houston

92123

Pfizer Investigational Site, San Diego

92801

Pfizer Investigational Site, Anaheim

06030-0001

Pfizer Investigational Site, Farmington

06708

Pfizer Investigational Site, Waterbury

60612-7323

Pfizer Investigational Site, Chicago

23320-1706

Pfizer Investigational Site, Chesapeake

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00137033 - Celebrex Low Dose ASA Study Examining the Incidence of Gastroduodenal Ulcers in a Healthy Population | Biotech Hunter | Biotech Hunter